跳至主要内容
临床试验/NCT00551577
NCT00551577Unknown2 期

Prospective, Randomized Phase II Clinical Trial to Select Primary Chemotherapy With Carboplatin and Docetaxel in Patients With Advanced Ovarian Cancer Stage FIGO IIIC and IV

University Hospital, Bonn4 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2003年3月1日最近更新:
适应症

试验速览

阶段
2 期
发起方
入组人数
100
试验地点
4
主要终点
Preoperative reduction of ascites volume

研究概览

简要总结

The purpose of this study is to evaluate response to neoadjuvant chemotherapy by imaging and observation of anatomical and biological indicators (i.e. ascites or continuous measurement of tumor marker CA 125). Furthermore the optimal number of preoperative administered cycles of combination chemotherapy with carboplatin and docetaxel should be determined.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • histological confirmed ovarian neoplasm
  • Figo stage IIIC (2cm extrapelvic disease) or Figo IV
  • more than 500 ml ascites volume (measured by sonography)
  • age > 18 years old
  • ECOG <= 2
  • adequate hepatological, renal and haematological function
  • informed consent

排除标准

  • concomitant or previous malignant diseases
  • debulking procedures on initial surgical approach
  • existing peripheral sensoric neuropathy >= grade 2
  • acute infections
  • mental disorders, cerebral metastasis
  • bowel obstruction

结局指标

主要结局

Preoperative reduction of ascites volume

时间窗: preoperative: after 2nd or 3rd cycle of chemotherapy (3-weekly course)

次要结局

  • Evaluation of overall response, Evaluation of postoperative tumor size, Evaluation of perioperative morbidity and mortality, QOL(6 months)

研究者

发起方
University Hospital, Bonn
申办方类型
Other

研究点 (4)

Loading locations...

相似试验

Neoadjuvant Chemotherapy With Carboplatin and... | 临床试验